Ceapro (TSXV:CZO) Common Stock : C$16.72 Mil (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is Ceapro Common Stock?

Ceapro's quarterly common stock increased from Jun. 2023 (C$16.70 Mil) to Sep. 2023 (C$16.72 Mil) but then stayed the same from Sep. 2023 (C$16.72 Mil) to Dec. 2023 (C$16.72 Mil).

Ceapro's annual common stock increased from Dec. 2021 (C$16.56 Mil) to Dec. 2022 (C$16.70 Mil) and increased from Dec. 2022 (C$16.70 Mil) to Dec. 2023 (C$16.72 Mil).

Ceapro Common Stock Historical Data

The historical data trend for Ceapro's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ceapro Common Stock Chart

Ceapro Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

16.40

16.51

16.56

16.70

16.72

Ceapro Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Common Stock	Get a 7-Day Free Trial															16.70	16.70	16.70	16.72	16.72

Ceapro Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Ceapro (TSXV:CZO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ceapro Inc (TSXV:CZO) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

CRPOF:USA

Address

7824-51 Avenue NW, Edmonton, AB, CAN, T6E 6W2

Website

https://www.ceapro.com

Ceapro Inc is engaged in the development and marketing of various health and wellness products and technology relating to plant extracts. Its operating segment is the active ingredient product technology industry which involves the development of proprietary extraction technologies and the application of these technologies to the production and development and commercialization of active ingredients derived from oats and other renewable plant resources for healthcare and cosmetic industries. Active ingredients produced include oat beta glucan and avenanthramides. The group derives revenue from the U.S., Germany, China, Canada and other countries, of which prime revenue is generated from the U.S.

Ceapro (TSXV:CZO) Headlines

No Headlines